Drugs / SAL056
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT07579936 | Apr → Jul 2026 overdue | postmenopausal osteoporosis | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07028320 | Dec 2021 → Dec 2023 | postmenopausal osteoporosis | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SAL056 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07028320 ↗ |
| Known as | Recombinant Human Parathyroid Hormone [1-34] | “SAL056 (Recombinant Human Parathyroid Hormone [1-34] for Injection [56.5 μg])” NCT07579936 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant Human Parathyroid Hormone [1-34] for Injection” NCT07579936 ↗ |
| Route | Subcutaneous | “Administered by subcutaneous injection once a week during treatment phase” NCT07028320 ↗ |